Vancouver, B.C. / TheNewswire / February 8, 2017 – MYM Nutraceuticals Inc. (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that Ian Ramage has been appointed to the Company’s Board of Directors.

 

Ian Ramage holds a B.A.Sc. in Computer Engineering from Simon Fraser University and J.D. and LL.M. degrees from the University of British Columbia. He practiced law in the Bay Area for eight years for a variety of biotech and high-tech clients before returning to Vancouver in 2009 to continue to build his corporate and securities practice. Mr. Ramage is a strong believer in the efficacy of medical marijuana and has advised numerous companies in the industry. He looks forward to bringing his expertise to MYM.

 

Mr. Ramage has been granted 250,000 incentive stock options (the “Options”), exercisable at a price of $ 0.20 per share. The Options, which will vest quarterly for one year and are exercisable for a period of two years from the date of grant, are subject to the policies of the Canadian Securities Exchange.

 

Jonathan Fiteni, CEO, commented: “Building our board of directors and bringing on individuals who are experts in key areas of our business was a major goal we set in 2016.  I am happy to welcome Mr. Ramage to the MYM team and am excited for the opportunity to work with him as we continue our pursuit of creating a vertically integrated company.  With this addition to our board we will be able to more effectively vet assets and opportunities in Canada and abroad.”

 

Correction:  MYM’s news release dated February 1, 2017 contained two typographical errors: “(stage 4 of 5)” should have read “(stage 6 of 7)” and “stage 5” should have read “stage 7”.  We apologize for any confusion this may have caused. For clarification, the company in which MYM has acquired a majority interest, Sublime Culture Inc., is in the penultimate stage of the ACMPR licensing process: pre-licensing inspection.  MYM will assist Sublime in completing its facility and preparing it for inspection. If the facility passes inspection, MYM and Sublime will be granted a license to produce medical marijuana under the Regulations.  

 

ABOUT MYM

MYM Nutraceuticals Inc. (CSE:MYM) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic medicinal marijuana supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.

MYM has identified the potential market in providing extraction and processing services to large and independent ACMPR farming operations looking to produce high quality plant extracts using top quality C02 extraction equipment and customized formulations.  Further to this business model is the ability to provide these services on-site via mobile convoy.

ON BEHALF OF THE BOARD

 

“Jonathan Fiteni”

 

Jonathan Fiteni

CEO and Director

Telephone: 778-317-7932

Email: info@mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.